BLT 5.77% 5.5¢ benitec biopharma limited

Axovant raises 40 mil, page-2

  1. 871 Posts.
    lightbulb Created with Sketch. 60
    https://www.sec.gov/Archives/edgar/data/1636050/000104746919001193/a2238033z424b5.htm

    The AXO-AAV-OPMD clinical program is expected to begin in the second half of 2019, and the final design will be informed by discussions with the FDA andother regulators.

    from the Axovant prospectus:

    Gene Therapy Program
    Clinical Indication Development Stage
    1

    AXO-AAV-GM1

    GM1 gangliosidosisClinical-ready
    2

    AXO-AAV-GM2

    GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease)

    Clinical

    3

    AXO-LENTI-PD

    Parkinson's disease

    Clinical

    4

    AXO-AAV-OPMD

    Oculopharyngeal muscular dystrophy

    Preclinical

    5

    AXO-AAV-ALS

    Amyotrophic lateral sclerosis

    Research

    6

    AXO-AAV-FTD

    Frontotemporal dementia

    Research

    7

    Four additional AXO-AAV

    Undisclosed

    Research

    8

    Collaboration Programs

 
watchlist Created with Sketch. Add BLT (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.